C. İrkeç Et Al. , "Investigation of the Effects of CX3CL1 on Immunopathogenesis and Cognitive Functions in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients in Terms of the Possibility of a Biomarker.," 5. Uluslararası Türk Dünyası Multipl Skleroz Kongresi. , Baku, Azerbaijan, 2023
İrkeç, C. Et Al. 2023. Investigation of the Effects of CX3CL1 on Immunopathogenesis and Cognitive Functions in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients in Terms of the Possibility of a Biomarker.. 5. Uluslararası Türk Dünyası Multipl Skleroz Kongresi. , (Baku, Azerbaijan).
İrkeç, C., Kuz, T., Eruyar, E., & Fidan, I., (2023). Investigation of the Effects of CX3CL1 on Immunopathogenesis and Cognitive Functions in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients in Terms of the Possibility of a Biomarker. . 5. Uluslararası Türk Dünyası Multipl Skleroz Kongresi., Baku, Azerbaijan
İrkeç, CEYLA Et Al. "Investigation of the Effects of CX3CL1 on Immunopathogenesis and Cognitive Functions in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients in Terms of the Possibility of a Biomarker.," 5. Uluslararası Türk Dünyası Multipl Skleroz Kongresi., Baku, Azerbaijan, 2023
İrkeç, CEYLA Et Al. "Investigation of the Effects of CX3CL1 on Immunopathogenesis and Cognitive Functions in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients in Terms of the Possibility of a Biomarker.." 5. Uluslararası Türk Dünyası Multipl Skleroz Kongresi. , Baku, Azerbaijan, 2023
İrkeç, C. Et Al. (2023) . "Investigation of the Effects of CX3CL1 on Immunopathogenesis and Cognitive Functions in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients in Terms of the Possibility of a Biomarker.." 5. Uluslararası Türk Dünyası Multipl Skleroz Kongresi. , Baku, Azerbaijan.
@conferencepaper{conferencepaper, author={CEYLA İRKEÇ Et Al. }, title={Investigation of the Effects of CX3CL1 on Immunopathogenesis and Cognitive Functions in Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients in Terms of the Possibility of a Biomarker.}, congress name={ 5. Uluslararası Türk Dünyası Multipl Skleroz Kongresi.}, city={Baku}, country={Azerbaijan}, year={2023}}